Menu Search
Equities

Abbott Laboratories

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ABL:HAN

Abbott Laboratories

Actions
  • Price (EUR)112.28
  • Today's Change-2.72 / -2.37%
  • Shares traded45.00
  • 1 Year change+18.54%
  • Beta0.7120
Data delayed at least 15 minutes, as of Jul 11 2025 16:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Abbott Laboratories grew revenues 4.59% from 40.11bn to 41.95bn while net income improved 134.18% from 5.72bn to 13.40bn.
Gross margin56.06%
Net profit margin31.89%
Operating margin16.41%
Return on assets17.54%
Return on equity30.82%
Return on investment21.36%
More ▼

Cash flow in USDView more

In 2024, Abbott Laboratories increased its cash reserves by 10.44%, or 720.00m. The company earned 8.56bn from its operations for a Cash Flow Margin of 20.40%. In addition the company used 2.34bn on investing activities and also paid 5.40bn in financing cash flows.
Cash flow per share9.54
Price/Cash flow per share13.78
Book value per share28.05
Tangible book value per share11.03
More ▼

Balance sheet in USDView more

Abbott Laboratories has a Debt to Total Capital ratio of 21.25%, a lower figure than the previous year's 32.40%.
Current ratio1.78
Quick ratio1.27
Total debt/total equity0.2713
Total debt/total capital0.2125
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)1.60%
Div growth rate (5 year)11.44%
Payout ratio (TTM)29.45%
EPS growth(5 years)30.55
EPS (TTM) vs
TTM 1 year ago		140.25
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.